A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer - ND

• Register: EUCTR
• Last refreshed on: 10 June 2014
• Main ID: EUCTR2008-007803-10-IT
• Date of registration: 30/06/2009
• Prospective Registration: Yes
• Primary sponsor: Wyeth Research, Division on Wyeth Pharmaceuticals, Inc.
• Public title: A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer - ND
• Scientific title: A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer - ND
• Date of first enrolment: 30/10/2009
• Target sample size: 1200
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-007803-10
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no

Countries of recruitment

Bulgaria, Denmark, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Portugal, Spain, United Kingdom

Key inclusion & exclusion criteria

Inclusion criteria:
1. Female subjects aged 18 years or older. 2. Histologically and/or cytologically confirmed diagnosis of breast cancer. 3. Locally recurrent or metastatic breast cancer that is not amenable to curative surgery and/or radiation. 4. Documentation of erbB-2 gene amplification by FISH (as defined by a ratio >2.2) or chromogenic in situ hybridization (CISH, as defined by the manufacturer?s kit instruction) or documentation of erbB-2-overexpression by IHC (defined as IHC3+, or IHC2+ with FISH or CISH confirmation) based on local laboratory or initial diagnostic results utilizing 1 of the sponsor-approved assays. If erbB-2 status is unavailable or was determined using a test other than a sponsor-approved assay and cannot be assessed using 1 of these assays prior to randomization, testing and study eligibility must be obtained from the sponsor-identified central laboratory prior to randomization. 5. All subjects must have tumor tissue (ie, most recent archived formalin fixed-embedded tissue [block or unstained slides]) available for central review of erbB-2 expression levels by FISH testing performed by the sponsor-identified central laboratory. 6. Documentation of ER/PgR status (positive or negative) based on local laboratory or initial diagnostic results must be available before study entry. If results are unavailable, tumor tissue may be sent to the sponsor-identified central vendor for assessment prior to study entry as per investigator?s discretion. 7. At least 1 measurable lesion as de fined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. 8. Eastern Cooperative Oncology Group (ECOG) status of 0 to 2 (not declining within 2 weeks prior to signing informed consent). 9. Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by multiple gated acquisition (MUGA) or echocardiogram (ECHO). 10. Screening laboratory values within the following parameters: Absolute neutrophil count (ANC) &#61619; 1.5 x 109 /L (1500/mm3) Platelet count &#61619;100 x 109/L (100,000/mm3) Hemoglobin &#61619;9.0 g/dL (90 g/L) Serum creatinine &#61603;1.5 x upper limit of normal (ULN) Total bilirubin &#61603;1.5 x ULN (<3 ULN if Gilbert?s disease) Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &#61603;2.5 x ULN (&#61603;5 x ULN if liver metastases are present) 11. Recovery (to grade 1 or baseline) from all clinically significant acute adverse effects of prior therapies (excluding alopecia). 12. All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control starting 2 weeks prior to the administration of the first dose of investigational product until 28 days after the last dose of investigational product. A woman of childbearing potential is one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1.Prior systemic anticancer therapy (including cytotoxic chemotherapy, signal transduction inhibitors [eg, lapatinib], biologic [eg, trastuzumab], or other investigational anticancer therapy) for locally recurrent or metastatic disease. Prior endocrine therapy in any setting is allowed. 2.Prior treatment with an erbB-2 inhibitor, other than trastuzumab, lapatinib, or the combination of the two, in the neoadjuvant or adjuvant setting. 3.Prior treatment with neoadjuvant or adjuvant anthracyclines with a cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose >800 mg/m2, or the equivalent dose for other anthracyclines or derivatives (eg, 72 mg/m2 of mitoxantrone). 4.Subjects with recurrence or progression of disease within 12 months after completion of adjuvant or neoadjuvant systemic anticancer therapy (including cytotoxic chemotherapy, signal transduction inhibitors [eg, lapatinib], biologic [eg, trastuzumab], or other investigational anticancer therapy), other than endocrine therapy, for early breast cancer. 5.Subjects with bone or skin as the only site of measurable disease. Subjects with skin lesions measurable by computed tomography (CT) scans or magnetic resonance imaging (MRI) as only site of measurable disease are allowed. 6.Major surgery, chemotherapy, radiotherapy, any investigational agents, or other cancer therapy within 2 weeks before the administration of the first dose of investigational product. 7.Active uncontrolled or symptomatic CNS metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Subjects with a history of CNS metastases or cord compression are eligible if they have been definitively treated and are off anticonvulsants and steroids for at least 4 weeks before first dose of investigational product. 8.Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association [NYHA] functional classification of &#8805;3), unstable angina, and myocardial infarction (within 12 months of study entry). 9.Inadequately controlled hypertension (ie, systolic blood pressure [BP] > 180 mm Hg or diastolic BP > 100 mm Hg). 10.Family history of congenital long or short QT syndrome, Brugada syndrome or QT/QTc interval > 0.45 second or known history of QT/QTc prolongation or torsade de pointe (TdP). 11.Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn?s disease, malabsorption, or grade &#8805;2 diarrhea of any etiology at baseline). 12.Preexisting grade 2 or greater motor or sensory neuropathy. 13.History of life-threatening hypersensitivity reaction to taxanes or trastuzumab. 14.Clinical contraindication to steroids preventing their use as part of paclitaxel premedication. 15.Women who are pregnant, breast-feeding, or women of childbearing potential who are not using effective contraception during participation in the study and do not agree to do so for at least 28 days after final dose of investigational product. 16.Inability or unwillingness to swallow oral medications. 17.Immunocompromised subjects, including known seropositivity for human immunodeficiency virus (HIV), or current or chronic hepatitis B and/or hepatitis C infection (as detected by positive testing for hepatitis B surface antigen [HbsAg] or antibody to hepatitis C virus [anti HCV] with confirmatory testing). (Note: testing is not mandatory to be eligible for the study. However if a subject is at risk for ha

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

ErbB2 Positive Locally Recurrent or Metastatic Breast Cancer.
MedDRA version: 12.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer

Intervention(s)

Product Name: neratinib
Product Code: HKI-272
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: neratinib
CAS Number: 698387-09-06
Current Sponsor code: HKI-272
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-

Trade Name: Herceptin
Pharmaceutical Form: Powder for infusion*
INN or Proposed INN: Trastuzumab
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-

Trade Name: Paclitaxel 6 mg/ml Concentrate for Solution for Infusion
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: Paclitaxel
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 6-

Primary Outcome(s)

Primary end point(s): The primary endpoint is PFS, defined as time from date of randomization to date of progressive disease (PD) or death if no progression. The secondary endpoints include OS, ORR, CBR, DOR, breast cancer specific quality of life, safety, CNS criteria, and biomarkers.

Secondary Objective: To compare independently assessed clinical activity between treatment arms by measuring: overall survival (OS), ORR, and duration of response (DOR) and clinical benefit rate (CBR; CR + PR + stable disease [SD] &#8805; 24 weeks). To compare safety (AEs; serious adverse events [SAEs]) between treatment arms. To compare patient reported breast specific quality of life between treatment arms. To compare the frequency of and time to symptomatic or progressive central nervous system (CNS) lesions between treatment arms.

Main Objective: To compare the independently assessed progression free survival (PFS) following treatment with neratinib in combination with paclitaxel versus trastuzumab plus paclitaxel in subjects who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer.

Secondary ID(s)

2008-007803-10-HU

3144A2-3005-WW